Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS G12C inhibitor HYP-2090PTSA

An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor HYP-2090PTSA selectively targets the KRAS G12C mutant and inhibits KRAS G12C-mediated signaling. This may halt proliferation and metastasis in KRAS G12C mutated tumor cells. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis. HYP-2090PTSA may also inhibit phosphatidylinositol 3-kinase (PI3K) activity and PI3K/Akt (protein kinase B)-mediated signaling pathway.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PI3K/KRAS G12C inhibitor HYP-2090PTSA
Code name:HYP 2090PTSA
HYP-2090PTSA
HYP2090PTSA
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search